Drug intelligence / Profile preview

anti-HMW-MAA IgG1 antibody

Development stage
Preclinical
Lead developer
IGEM Therapeutics
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

The anti-HMW-MAA IgG1 antibody is a monoclonal antibody of the IgG1 isotype that targets High Molecular Weight Melanoma-Associated Antigen (HMW-MAA), also known as Chondroitin Sulfate Proteoglycan 4 (CSPG4). HMW-MAA is a surface antigen highly expressed on melanoma cells and various other solid tumors, where it plays a role in tumor growth and metastasis. This specific IgG1 construct was developed primarily as a benchmark or comparator molecule by researchers associated with King's College London and IGEM Therapeutics to evaluate the efficacy of an IgE-class version of the same antibody. In preclinical studies, the IgG1 antibody has demonstrated the ability to induce antibody-dependent cell-mediated phagocytosis (ADCP) and antibody-dependent cell-mediated cytotoxicity (ADCC) against melanoma cells, although it is often reported as less potent than its IgE counterpart in certain in vivo models.

Other names
anti-CSPG4 IgG1 antibodyanti-CSPG-4 IgG1 antibodyanti-CSPG 4 IgG1 antibodyanti-chondroitin sulfate proteoglycan 4 IgG1 antibodyanti-HMW-MAA IgG1
02

Targets

CSPG4 (Chondroitin sulfate proteoglycan 4)

Beyond the preview

Go deeper on anti-HMW-MAA IgG1 antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-HMW-MAA IgG1 antibody.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call